A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases.

作者：Ting Li, Biyun Wang, Zhonghua Tao, Mingchuan Zhao, Leiping Wang, Juan Jin, Yannan Zhao, Chengcheng Gong, Jun Cao, Haitao Miao, Jianfei Wang, Xichun Hu, Jian Zhang · 发表于：Journal of Clinical Oncology · 年份：2025 · DOI：10.1200/jco.2025.43.16_suppl.1018 · 被引用次数：3 · 研究领域：Brain Metastases and Treatment、Cancer Treatment and Pharmacology、Lung Cancer Research Studies

1018 Background: Brain metastases (BMs) of triple-negative breast cancer (TNBC) is a lethal disease often associated with a limited life span of approximately 6 months and local therapy is usually the first treatment choice due to lack of effective anti-tumor agents. Here reported a triplet, anti-PD-L1 (Adebrelimab, SHR-1316), bevacizumab plus cisplatin/carboplatin in BMs of triple negative breast cancer. Methods: This is a single center, single-arm, phase II clinical trial involving triple-negative breast cancer patients with active brain metastases. A total of 35 participants were administered a triplet treatment consisting of Adebrelimab, bevacizumab and cisplatin/carboplatin. Prior use of bevacizumab or anti-PD-1/PD-L1 was not allowed. Prior use of platinum was allowed only in cases with platinum-sensitive disease. The primary endpoint was the objective response rate in the central nervous system (CNS-ORR), and the secondary endpoints included the clinical benefit rate in CNS (CNS-CBR), progression-free survival (PFS), overall survival (OS), the first progression site and safety. Results: The data cutoff for this analysis was on December 20, 2024. A total of 35 patients enrolled in this study from August 2020 to October 2024. Among all patients, 42.9% (15/35) had neurological symptoms at baseline, and 80% (28/35) had not received any local treatment for their brain metastases. The median number of previous lines of therapy for metastatic disease was 2 (range 0-4), with 40...